The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
33 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $66,716,988 in first-year total cost, median $1,883,919.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RPRB-C (J1)]4
- Special Emphasis Panel[ZCA1 RPRB-O (M1)]4
- Special Emphasis Panel[ZCA1 RPRB-B (J1)]3
- Special Emphasis Panel[ZCA1 RPRB-F (J1)]3
- Special Emphasis Panel[ZCA1 RPRB-6 (M1)]2
Most frequent institutions
- DANA-FARBER CANCER INST4
- UNIVERSITY OF MINNESOTA3
- MEDICAL UNIVERSITY OF SOUTH CAROLINA2
- UNIV OF NORTH CAROLINA CHAPEL HILL2
- UNIVERSITY OF PENNSYLVANIA2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Risk-based Breast Cancer Screening and Surveillance in Community Practice2P01CA154292-06 | KERLIKOWSKE, KARLA MMIGLIORETTI, DIANA LTOSTESON, ANNA N. A. | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $3,500,336 | ZCA1 |
| 2017 | Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 191P01CA214278-01 | JUNE, CARL H. | UNIVERSITY OF PENNSYLVANIA, PA | $2,897,444 | ZCA1 |
| 2017 | Consortium on Methods Evaluating Tobacco (COMET): FilterVentilation and Product Standards1P01CA217806-01 | HATSUKAMI, DOROTHY KSHIELDS, PETER G. | UNIVERSITY OF MINNESOTA, MN | $2,796,778 | ZCA1 |
| 2017 | I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes1P01CA210961-01A1 | ESSERMAN, LAURA JHYLTON-WATSON, NOLA M. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $2,339,503 | ZCA1 |
| 2017 | Radiation and checkpoint blockade for cancer immune therapy1P01CA210944-01 | MAITY, AMITMINN, ANDY JVONDERHEIDE, ROBERT HWHERRY, E. JOHN | UNIVERSITY OF PENNSYLVANIA, PA | $2,329,233 | ZCA1 |
| 2017 | Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance1P01CA217959-01 | MARIS, JOHN MSEEGER, ROBERT CHARLES | CHILDREN'S HOSPITAL OF LOS ANGELES, CA | $2,296,936 | ZCA1 |
| 2017 | Integration of Clinical and Molecular Biomarkers for Melanoma Survival1P01CA206980-01A1 | BERWICK, MARIANNETHOMAS, NANCY E. | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | $2,292,665 | ZCA1 |
| 2017 | Integrative Oncogenomics of Multiple Myeloma2P01CA155258-06 | MUNSHI, NIKHIL C. | DANA-FARBER CANCER INST, MA | $2,086,676 | ZCA1 |
| 2017 | Roles and Regulation of wild-type and mutant forms of p532P01CA087497-16A1 | PRIVES, CAROLSTOCKWELL, BRENT R. | COLUMBIA UNIV NEW YORK MORNINGSIDE, NY | $1,945,587 | ZCA1 |
| 2017 | Processing and Repair of DNA Crosslinks1P01CA193124-01A1 | WOOD, RICHARD D | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $1,883,919 | ZCA1 |
| 2017 | Structure and Function of DNA Repair Enzymes and Cancer2P01CA098993-11A1 | DOUBLIE, SYLVIE | UNIVERSITY OF VERMONT & ST AGRIC COLLEGE, VT | $1,862,974 | ZCA1 |
| 2017 | Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma2P01CA154303-06 | MEYERSON, MATTHEW L. | DANA-FARBER CANCER INST, MA | $1,846,248 | ZCA1 |
| 2017 | Maximizing Local Access to Therapeutic Deliveries in Glioblastoma1P01CA207206-01A1 | DEBINSKI, WALDEMAR | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $1,793,324 | ZCA1 |
| 2017 | RXR Rexinoids for Cancer Chemoprevention1P01CA210946-01A1 | ELMETS, CRAIG A | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $1,770,718 | ZCA1 |
| 2017 | Human Cancer Suppressor Functions of Protein Phosphatase 2A1P01CA203655-01A1 | DECAPRIO, JAMES A. | DANA-FARBER CANCER INST, MA | $1,613,905 | ZCA1 |
| 2017 | Characterization of Pathways Controlling Cancer at the Level of Gene Regulation2P01CA042063-31 | JACKS, TYLER E. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $1,401,672 | ZCA1 |
| 2017 | Extracellular Vesicles (EVs) and Genes in the Biology and Therapy of Gliomas2P01CA069246-20 | BREAKEFIELD, XANDRA OWENSCHIOCCA, E. ANTONIO | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,387,951 | ZCA1 |
| 2017 | Noncoding RNAs in gamma-Herpesvirus Biology and AIDS Malignancies1P01CA214091-01 | RENNE, ROLF F | UNIVERSITY OF FLORIDA, FL | $1,356,357 | ZCA1 |
| 2017 | Integrative analysis of lung cancer etiology and risk1U19CA203654-01A1 | AMOS, CHRISTOPHER I.BRENNAN, PAUL JOSEPHHUNG, RAYJEAN J.LIN, XIHONG | DARTMOUTH COLLEGE, NH | $173,154 | ZCA1 |
| 2016 | Evaluating How Tobacco Control Policies are Shaping the Nicotine Delivery Market1P01CA200512-01 | CUMMINGS, KENNETH MICHAELFONG, GEOFFREY T | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $3,306,202 | ZCA1 |
| 2016 | Structural Cell Biology of DNA Repair Machines2P01CA092584-16 | TAINER, JOHN A. | UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB, CA | $3,085,532 | ZCA1 |
| 2016 | Statistical Methods for Integrative Genomics in Cancer1P01CA196569-01A1 | GAUDERMAN, WILLIAM JAMESTHOMAS, DUNCAN C. | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $2,549,526 | ZCA1 |
| 2016 | Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking2P01CA138338-06 | HECHT, STEPHEN S | UNIVERSITY OF MINNESOTA, MN | $2,301,497 | ZCA1 |
| 2016 | Genetics and Biology of Pancreatic Ductal Adenocarcinoma2P01CA117969-11 | DEPINHO, RONALD ANTHONY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $2,143,865 | ZCA1 |
| 2016 | NK cells, their receptors, transplantation and cancer therapy2P01CA111412-11A1 | MILLER, JEFFREY S. | UNIVERSITY OF MINNESOTA, MN | $1,960,158 | ZCA1 |
| 2016 | Cellular and Molecular Studies of Bone Marrow Transplant2P01CA039542-28A1 | FERRARA, JAMES L. M. | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $1,959,918 | ZCA1 |
| 2016 | Herpesviral Oncogenesis, Latency and Reactivation2P01CA019014-37 | DAMANIA, BLOSSOM ARAAB-TRAUB, NANCY JOAN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $1,811,800 | ZCA1 |
| 2016 | Development of Novel Cancer Therapeutics by Targeting Sphingolipid Signaling1P01CA203628-01 | OGRETMEN, BESIM | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $1,811,148 | ZCA1 |
| 2016 | Integrated EGFR function in cytokine-driven inflammation and cancer2P01CA062220-21 | STARK, GEORGE ROBERT | CLEVELAND CLINIC LERNER COM-CWRU, OH | $1,805,475 | ZCA1 |
| 2016 | ER Stress and Mitochondrial Biogenesis in Melanoma2P01CA128814-06A1 | RONAI, ZEEV A. | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $1,768,606 | ZCA1 |
| 2016 | Comprehensive dissection of the CLL genome and phenome to improve patient outcomes1P01CA206978-01 | WU, CATHERINE JU-YING | DANA-FARBER CANCER INST, MA | $1,755,838 | ZCA1 |
| 2016 | Defining RAS isoform- and mutation-specific roles in oncogenesis1P01CA203657-01 | DER, CHANNING J. | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $1,609,721 | ZCA1 |
| 2016 | Novel Molecular Therapies of Prostate Cancer2P01CA140043-07A1 | ALTIERI, DARIO C | WISTAR INSTITUTE, PA | $1,272,322 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.